STAT+: Capricor Therapeutics accuses Nippon Shinyaku of slow-walking plans on Duchenne drug

Capricor Therapeutics accuses Nippon Shinyaku of failing to follow through on marketing plans for a Duchenne muscular dystrophy treatment. A pricing glitch in their distribution agreement would make the therapy economically impractical for patients covered by Medicare, Medicaid, and private insurers. The issue was disclosed in March 2025.